A case of successful pregnancy in a woman with previous episodes of unprovoked deep vein thrombosis treated with vitamin K antagonist (warfarin) therapy is described. As the patient became pregnant, warfarin therapy was immediately stopped and lowmolecular-weight heparin (LMWH) prophylaxis was started. In the second and third trimesters of pregnancy we observed an increase in body weight (from 64 to 80 kg) and in body mass index (from 21 to 26.4). During the pregnancy, we used the heparin-anti factor Xa assay (Anti-FXa) to monitor the LMWH treatment and to adjust the dosage in a increasing way. The Anti-FXa can be very useful in improving safety and efficacy of LMWH treatment in pregnancy.
[Utilità della misura dell’attività plasmatica di eparina-anti fattore Xa durante trattamento antitrombotico in gravidanza] Usefulness of heparin-anti factor Xa assay during antithrombotic treatment in pregnancy
FACCHINETTI, ROBERTO
2013-01-01
Abstract
A case of successful pregnancy in a woman with previous episodes of unprovoked deep vein thrombosis treated with vitamin K antagonist (warfarin) therapy is described. As the patient became pregnant, warfarin therapy was immediately stopped and lowmolecular-weight heparin (LMWH) prophylaxis was started. In the second and third trimesters of pregnancy we observed an increase in body weight (from 64 to 80 kg) and in body mass index (from 21 to 26.4). During the pregnancy, we used the heparin-anti factor Xa assay (Anti-FXa) to monitor the LMWH treatment and to adjust the dosage in a increasing way. The Anti-FXa can be very useful in improving safety and efficacy of LMWH treatment in pregnancy.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
